CN107531702A - 氨基脲敏感性胺氧化酶（ssao）抑制剂的药用盐形式 - Google Patents

氨基脲敏感性胺氧化酶（ssao）抑制剂的药用盐形式 Download PDF

Info

Publication number
CN107531702A
CN107531702A CN201680023326.3A CN201680023326A CN107531702A CN 107531702 A CN107531702 A CN 107531702A CN 201680023326 A CN201680023326 A CN 201680023326A CN 107531702 A CN107531702 A CN 107531702A
Authority
CN
China
Prior art keywords
disease
compound according
inflammatory
tetrahydro
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680023326.3A
Other languages
English (en)
Chinese (zh)
Inventor
爱德华·萨沃里
迈克尔·希金博特姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BenevolentAI Cambridge Ltd
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Priority to CN202110072000.2A priority Critical patent/CN112851669A/zh
Publication of CN107531702A publication Critical patent/CN107531702A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201680023326.3A 2015-04-24 2016-04-22 氨基脲敏感性胺氧化酶（ssao）抑制剂的药用盐形式 Pending CN107531702A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110072000.2A CN112851669A (zh) 2015-04-24 2016-04-22 氨基脲敏感性胺氧化酶（ssao）抑制剂的药用盐形式

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1507031.1A GB201507031D0 (en) 2015-04-24 2015-04-24 New pharmaceutical salt forms
GB1507031.1 2015-04-24
PCT/GB2016/051119 WO2016170351A1 (en) 2015-04-24 2016-04-22 Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110072000.2A Division CN112851669A (zh) 2015-04-24 2016-04-22 氨基脲敏感性胺氧化酶（ssao）抑制剂的药用盐形式

Publications (1)

Publication Number Publication Date
CN107531702A true CN107531702A (zh) 2018-01-02

Family

ID=53488629

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680023326.3A Pending CN107531702A (zh) 2015-04-24 2016-04-22 氨基脲敏感性胺氧化酶（ssao）抑制剂的药用盐形式
CN202110072000.2A Pending CN112851669A (zh) 2015-04-24 2016-04-22 氨基脲敏感性胺氧化酶（ssao）抑制剂的药用盐形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110072000.2A Pending CN112851669A (zh) 2015-04-24 2016-04-22 氨基脲敏感性胺氧化酶（ssao）抑制剂的药用盐形式

Country Status (19)

Country Link
US (1) US10316034B2 (enExample)
EP (1) EP3286190B1 (enExample)
JP (2) JP2018513189A (enExample)
KR (1) KR20170139045A (enExample)
CN (2) CN107531702A (enExample)
AR (1) AR104360A1 (enExample)
AU (1) AU2016251707B2 (enExample)
BR (1) BR112017020016A2 (enExample)
CA (1) CA2979144A1 (enExample)
DK (1) DK3286190T3 (enExample)
EA (1) EA035668B1 (enExample)
ES (1) ES2804155T3 (enExample)
GB (1) GB201507031D0 (enExample)
HU (1) HUE049985T2 (enExample)
IL (1) IL254153A0 (enExample)
MX (1) MX2017013049A (enExample)
PT (1) PT3286190T (enExample)
SG (1) SG11201707867WA (enExample)
WO (1) WO2016170351A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108017634A (zh) * 2017-12-15 2018-05-11 清华大学 一种制备吡咯并多环衍生物的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain
GB201618029D0 (en) 2016-10-25 2016-12-07 Proximagen Ltd New process

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102232073A (zh) * 2008-09-16 2011-11-02 普罗克西梅根有限公司 新化合物i
CN103797012A (zh) * 2011-09-14 2014-05-14 普罗克斯马根有限公司 新的酶抑制剂化合物
CN103889983A (zh) * 2011-09-14 2014-06-25 普罗克西梅根有限公司 新型酶抑制剂化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141899A (en) 1976-01-07 1979-02-27 Societa' Farmaceutici Italia S.P.A. 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
IT1098015B (it) 1978-08-07 1985-08-31 Farmaceutici Italia Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati
EP1173438A1 (en) * 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
SE0004101D0 (sv) 2000-11-09 2000-11-09 Pharmacia Ab New use
AU2002214505A1 (en) 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
CA2556914A1 (en) * 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
US20070066646A1 (en) 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
EP2029164B1 (en) 2006-06-07 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
JP5613671B2 (ja) * 2008-09-16 2014-10-29 プロキシマジェン エルティーディーＰｒｏｘｉｍａｇｅｎ Ｌｔｄ． 新規化合物ｉｉ
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
HUE042625T2 (hu) 2014-04-15 2019-07-29 Pecsi Tudomanyegyetem Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102232073A (zh) * 2008-09-16 2011-11-02 普罗克西梅根有限公司 新化合物i
CN103797012A (zh) * 2011-09-14 2014-05-14 普罗克斯马根有限公司 新的酶抑制剂化合物
CN103889983A (zh) * 2011-09-14 2014-06-25 普罗克西梅根有限公司 新型酶抑制剂化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARRY G. BRITTAIN: "Developing an Appropriate Salt Form for an Active", 《AMERICAN PHARMACEUTICAL REVIEW》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108017634A (zh) * 2017-12-15 2018-05-11 清华大学 一种制备吡咯并多环衍生物的方法

Also Published As

Publication number Publication date
IL254153A0 (en) 2017-10-31
HK1249906A1 (en) 2018-11-16
US10316034B2 (en) 2019-06-11
SG11201707867WA (en) 2017-11-29
AU2016251707B2 (en) 2020-02-20
MX2017013049A (es) 2017-12-08
JP2018513189A (ja) 2018-05-24
GB201507031D0 (en) 2015-06-10
EA201792121A1 (ru) 2018-03-30
EA035668B1 (ru) 2020-07-23
CN112851669A (zh) 2021-05-28
BR112017020016A2 (pt) 2018-06-19
DK3286190T3 (da) 2020-07-13
US20180111928A1 (en) 2018-04-26
EP3286190B1 (en) 2020-06-03
CA2979144A1 (en) 2016-10-27
HUE049985T2 (hu) 2020-11-30
WO2016170351A1 (en) 2016-10-27
AR104360A1 (es) 2017-07-12
JP2021073256A (ja) 2021-05-13
ES2804155T3 (es) 2021-02-04
AU2016251707A1 (en) 2017-10-05
EP3286190A1 (en) 2018-02-28
PT3286190T (pt) 2020-07-09
KR20170139045A (ko) 2017-12-18

Similar Documents

Publication Publication Date Title
JP2022071072A (ja) （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
JP2021073256A (ja) セミカルバジド感受性アミンオキシダーゼ（ｓｓａｏ）の阻害剤の医薬的塩形態
UA129636C2 (uk) Заміщена піперидинова сполука та її застосування
CN102639536B (zh) 吡啶衍生物的无水晶型
KR102788829B1 (ko) 야누스 키나제 억제제의 결정질 형태
US20170260167A1 (en) Synthesis and novel salt forms of (r)-5-((e)-2-pyrrolidin-3-ylvinyl)pyrimidine
US20240400566A1 (en) Solid polymorphs of a flna-binding compound and its hydrochloride salts
JP2021073259A (ja) セミカルバジド感受性アミンオキシダーゼ酵素阻害剤としての結晶性化合物
EP3279195A1 (en) Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
CN109715639B (zh) 结晶形式
JP5872105B2 (ja) ピロリジン−３−イル酢酸誘導体の塩およびその結晶
HK1249906B (en) Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao)
TW201710256A (zh) 新穎醫藥鹽形態及結晶形態
WO2022247772A1 (zh) 一种含氧杂环化合物的晶型、其制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: London, England

Applicant after: Boshan AI Cambridge Co., Ltd.

Address before: Cambridge County

Applicant before: Proximagen Limited

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20180102

RJ01 Rejection of invention patent application after publication